Valion Bio, Inc.
VBIO· Nasdaq
VBIOValion Bio, Inc.
Filed Mar 30, 2026 · 10-K · 89 days after period end · 0001437749-26-010343
derived · Computed from the longer spans the company filed.
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Revenue | — | $180.00K | $357.00K | $407.00K |
| Net Income | -$2.85M | -$1.48M | -$2.24M | -$2.25M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Valion Bio, Inc. · CIK 1787740 · Engraved from SEC EDGAR
ended Dec 31, 2025 · filed Mar 30, 2026 · 89 d after period end
